Omiloxetine

Omiloxetine

Systematic (IUPAC) name
2-[(3R,4S)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-piperidinyl]-1-(4-fluorophenyl)ethanone
Identifiers
CAS Number	176894-09-0
ATC code	None
PubChem	CID: 3047803
ChemSpider	2310120
UNII	H8YI0SSF7B
ChEMBL	CHEMBL2105290
Chemical data
Formula	C27H25F2NO4
Molecular mass	465.489 g/mol
SMILES Fc1ccc(cc1)C(=O)CN3CC[C@H](c2ccc(F)cc2)[C@H](C3)COc4ccc5OCOc5c4
InChI InChI=1S/C27H25F2NO4/c28-21-5-1-18(2-6-21)24-11-12-30(15-25(31)19-3-7-22(29)8-4-19)14-20(24)16-32-23-9-10-26-27(13-23)34-17-33-26/h1-10,13,20,24H,11-12,14-17H2/t20-,24-/m1/s1 Key:FAHGZANUNVVDFL-HYBUGGRVSA-N
Physical data
Density	1.3±0.1 g/cm3
Melting point	228.65 °C (443.57 °F)
Boiling point	587.2 °C (1,089.0 °F)
Solubility in water	0.0015 mg/mL (20 °C)

Omiloxetine (omiloextinum, omiloxetino INN) was a selective serotonin reuptake inhibitor drug candidate that underwent preclinical development by the Spanish pharmaceutical company, Ferrer Internacional, until 2005, when it was abandoned.